BIRC6 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9NR09 |
---|---|
Other Accession | NP_057336 |
Gene ID | 57448 |
---|---|
Other Names | Baculoviral IAP repeat-containing protein 6, 632-, BIR repeat-containing ubiquitin-conjugating enzyme, BRUCE, Ubiquitin-conjugating BIR domain enzyme apollon, APOLLON, BIRC6, KIAA1289 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6127a was selected from the N-term region of human BIRC6 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | BIRC6 |
---|---|
Synonyms | KIAA1289 |
Function | Anti-apoptotic protein which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Has an unusual ubiquitin conjugation system in that it could combine in a single polypeptide, ubiquitin conjugating (E2) with ubiquitin ligase (E3) activity, forming a chimeric E2/E3 ubiquitin ligase. Its targets include CASP9 and DIABLO/SMAC. Acts as an inhibitor of CASP3, CASP7 and CASP9. Important regulator for the final stages of cytokinesis. Crucial for normal vesicle targeting to the site of abscission, but also for the integrity of the midbody and the midbody ring, and its striking ubiquitin modification. |
Cellular Location | Golgi apparatus, trans-Golgi network membrane. Endosome Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Midbody, Midbody ring. Note=Exhibits cell cycle-dependent localization. Concentrates in a pericentriolar compartment in interphase, moves partially to spindle poles in metaphase, and finally localizes to the spindle midzone and the midbody in telophase and during cytokinesis. On the midbody, localizes to the midbody ring, also called Flemming body (PubMed:18329369). In interphase cells, localizes to the trans-Golgi network membrane and endosomes. During cytokinesis, a fraction moves to the midzone where it specifically arrives at the midbody ring. After abscission completion, travels with the midbody remnant into one daughter cell, and remains bound to it until a new midbody ring is formed during the next cell division (PubMed:18329369) |
Tissue Location | Expressed in brain cancer cells. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
BIRC6 is a member of a family of proteins that inhibit apoptosis, likely through interference with activation of ICE-like proteases. BIRC6, which contains a single BIR domain and a ubiquitin-conjugating enzyme domain, is expressed in four of six brain cancers (gliomas), and one of five ovarian cancers in a variety of human cancer cell lines. Brain cancer cell lines that overexpress BIRC6 demonstrate multi-drug resistance BIRC6 may protect cancer cells from undergoing apoptosis and participate in tumorigenesis and drug resistance.
References
Chen, Z., et al., Biochem. Biophys. Res. Commun. 264(3):847-854 (1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.